Group Leader - Saigenci

(Level C) $125, 537 to $144,368 per annum or (Level D) $150,639 to $165,698 per annum plus an employer contribution of up to 17% superannuation may apply

Multiple positions available in a fixed term, full-time position capacity for five years.

Exciting opportunity to join SAiGENCI as Group Leader in Cancer Research.

Generous five-year establishment grants to support additional postdoctoral staff and research costs will be offered.

Applications are invited from exceptionally motivated scientists with an ambitious and original vision for research that aligns with South Australian immunoGENomics Cancer Institute (SAiGENCI) core research programs. SAiGENCI is excited to be offering the opportunity for a Level C Senior Research Fellow or Level D Associate Professor (Research) to join its dynamic research leadership. SAiGENCI welcomes applications from individuals who seek to make major transformational discoveries running their independent research program and who wish to accelerate their scientific research career as a SAiGENCI Group Leader.

SAiGENCI operates as an independent institute within the University of Adelaide and in alliance with the Central Adelaide Local Health Network (CALHN). SAiGENCI supports and promotes collaborations with other cancer research centres in Australia. SAiGENCI aims to develop the highest quality scientific program to achieve its chief goal of making discoveries to decrease the burden of cancer, by attracting and retaining brilliant biomedical and clinical researchers. The Institute will also have a global reach by collaborating with likeminded centres of excellence across the globe.

SAiGENCI will provide a focal point for cancer research in the South Australian Biomedical Precinct and through this, enable South Australian participation in the developing Australian network of cancer institutes, and national and international clinical trials partnerships. In so doing, SAiGENCI will help develop world-class and life-changing treatments and improve the outcomes of patients with cancer.

We are now seeking to recruit an outstanding Research Group Leaders who will head up an independent research team undertaking research within one of four program themes:

Resistance Prevention

The program will work on understanding the mechanisms underlying response and resistance to contemporary cancer therapies. It is envisaged that laboratory findings will be translated directly from bench to bedside through clinical trials.

Cancer Epigenetics

The Cancer Epigenetic program, led by Professor Jose Polo, combines Cancer, Reprogramming and Epigenetics, using expertise in cellular reprogramming, epigenetics, stem cell biology and the characterisation of rare cell populations. In the last 14 years there has been a revolution in this field, leading to an explosion in the use of reprogramming in potential cellular therapies. This process can inform and help in cancer biology research. Tools and analytical methods to facilitate the understanding of the epigenetic mechanism underpinning several tumorigenic processes will be developed, where epigenetic and reprogramming research will also allow the discovery of new targets and, ultimately, therapies.

Computational Systems Oncology

The expert Computational Systems Biologist and Bioinformatics program, led by Professor Melissa Davis will create a centre of research excellence in advanced computational systems biology, taking advantage of novel technologies and high-density data from the clinic and laboratory, to develop new methods and research programs that will form an integral part of all of the basic and translational research excellence at SAiGENCI. The team is proving to act as a catalyst for several important relationships in computing and data analysis, enhancing the existing strengths of the University through the Australian Institute for Machine Learning (AIML) and other partners at SAHMRI.

Tumour Inflammation and Immunotherapy

The Tumour Inflammation and Immunotherapy program, led by Professor Brendan Jenkins, will aim to manipulate both innate and adaptive arms of the immune system, including augmentation of tumour antigenicity and modulation of the inflammatory response, as key strategies to suppress tumourigenesis. The program is seeking particular interest from leading researchers with expertise in NK and/or T cell-based immunotherapy or adaptive immunity. The cancer type to be targeted is not defined, with a tissue agnostic approach that has potential to apply to multiple cancers.

Enjoy an outstanding career environment

The University of Adelaide is a uniquely rewarding workplace. The size, breadth and quality of our education and research programs - including significant industry, government and community collaborations - offers you a vast scope and opportunity for a long, fulfilling career.

It also enables us to attract high-calibre people in all facets of our operations, ensuring you will be surrounded by talented colleagues, many world-leading. Our work's cutting-edge nature - not just in your own area, but across virtually the full spectrum of human endeavour - provides a constant source of inspiration.

Our culture is one that welcomes all and embraces diversity consistent with our and our values of integrity, respect, collegiality, excellence and discovery. We firmly believe that our people are our most valuable asset, so we work to grow and diversify the skills, knowledge and capability of all our staff.

We embrace flexibility as a key principle to allow our people to manage the changing demands of work, personal and family life. Flexible working arrangements are on offer for all roles at the University.

In addition, we offer a wide range of attractive staff benefits. These include: salary packaging; flexible work arrangements; high-quality professional development programs and activities; and an on-campus health clinic, gym and other fitness facilities.

Learn more at:

If you have the talent, we'll give you the opportunity. Together, let's make history.

Click on the link below for a copy of the position description and to apply:

Please ensure you submit a cover letter, resume, and upload a document that includes your responses to all of the selection criteria for the position as contained in the position description or selection criteria document.

Applications close 11:55pm, 13 April 2023.

For further information

For a confidential discussion regarding this position, contact the Program Leads:

Resistance Prevention
Professor Christopher Sweeney
Director, SAiGENCI
E:

Cancer Epigenetics
Professor Jose Polo
E:

Computational System Oncology
Professor Melissa Davis
E:

Tumour Inflammation and Immunotherapy
Professor Brendan Jenkins
E:

The University of Adelaide is an Equal Employment Opportunity employer committed to providing a working environment that embraces and values diversity and inclusion. Female applicants, people with a disability and/or and Aboriginal and Torres Strait Islander people who meet the requirements of this position are strongly encouraged to apply. If you have any support or access requirements, we encourage you to advise us at time of application.